In this important new white paper, Thomson Reuters reveals the true picture of the generic market in Japan, predicts how it may change under the incoming DPJ administration, and details the tactics that companies must follow to ensure success in this market. Subscribe

 

We show how the pharmaceutical industry is already beginning to rely on biomarker information, and explain how important it is to establish the standards that will support increasing biomarker implementation in the future. Subscribe

 

 

In this white paper, we explore the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents. The potential of biomarkers to improve decision making, accelerate drug development and reduce development costs is discussed with insight from experts in industry and academia. Subscribe

Also check out what Dr. Jeffery Ross has to say about Biomarkers by watching Biomarkers, Drug Development and the Advent of Personalized Medicine  Presented by Dr Jeffery Ross, Albany Medical College, New York

 

Objectively identifying key opinion leaders (KOLs), scientific experts or clinical investigators to collaborate with can be an onerous task.

Thomson Reuters discusses the regulatory aspects of the KOL / industry relationship, proposes a primary means of determining KOL relevance, discusses methods for identifying KOLs to suit your business strategy, and proposes a solution for optimal KOL identification and selection. Subscribe

 

The role of every brand manager, regardless of industry, is to ensure their company’s voice is heard over the background noise of the marketplace.

Unlike other industries, however, guaranteeing a positive reception for a new pharmaceutical product isn’t just a case of spending the most on advertising or sponsorship. There are strategies you must adopt in order to influence the market positively and make sure you realize the greatest possible return on your investment. Download